Population Approach To Analyze the Pharmacokinetics of Free and Total Lopinavir in HIV-Infected Pregnant Women and Consequences for Dose Adjustment

被引:14
作者
Fauchet, Floris [1 ,2 ]
Treluyer, Jean-Marc [1 ,2 ,3 ,4 ]
Illamola, Silvia M. [1 ,2 ]
Pressiat, Claire [1 ,2 ]
Lui, Gabrielle [1 ,2 ]
Valade, Elodie [1 ,2 ]
Mandelbrot, Laurent [5 ,6 ,7 ]
Lechedanec, Jerome [5 ]
Delmas, Sandrine [5 ,8 ]
Blanche, Stephane [1 ,9 ]
Warszawski, Josiane [5 ,8 ]
Urien, Saik [1 ,2 ,4 ]
Tubiana, Roland [10 ,11 ]
Hirt, Deborah [1 ,3 ]
机构
[1] Univ Paris 05, EA 08, Sorbonne Paris Cite, Paris, France
[2] Hop Tarnier, AP HP, Unite Rech Clin, Paris, France
[3] Grp Hosp Pris Ctr, AP HP, Serv Pharmacol Clin, Paris, France
[4] INSERM, CIC 0901, Paris, France
[5] Equipe VIH & IST, Ctr Res Epidemiol & Populat Hlth, INSERM, U1018, Le Kremlin Bicetre, France
[6] HUPNVS, Hop Louis Mourier, AP HP, Serv Gynecol & Obstet, Colombes, France
[7] Univ Paris 07, Paris, France
[8] Hop Bicetre, AP HP, Serv Epidemiol & Sante Publ, Le Kremlin Bicetre, France
[9] Hop Necker Enfants Malad, AP HP, Unite Immunol Hematol Pediat, Paris, France
[10] Univ Paris 06, Sorbonne Univ, Pierre Louis Inst Epidemiol & Publ Hlth, INSERM,UMRS 943, Paris, France
[11] GH Pitie Salpetriere, AP HP, Malad Infect, Paris, France
关键词
PLASMA-CONCENTRATIONS; PROTEASE INHIBITORS; MITOCHONDRIAL DYSFUNCTION; ANTIRETROVIRAL DRUGS; UNINFECTED CHILDREN; NUCLEOSIDE ANALOGS; EXPOSURE; RITONAVIR; BINDING; LOPINAVIR/RITONAVIR;
D O I
10.1128/AAC.00863-15
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The aims of this study were to describe the unbound and total lopinavir (LPV) pharmacokinetics in pregnant women in order to evaluate if a dosing adjustment is necessary during pregnancy. Lopinavir placental transfer is described, and several genetic covariates were tested to explain its variability. A total of 400 maternal, 79 cord blood, and 48 amniotic fluid samples were collected from 208 women for LPV concentration determinations and pharmacokinetics analysis. Among the maternal LPV concentrations, 79 samples were also used to measure the unbound LPV concentrations. Population pharmacokinetics models were developed by using NONMEM software. Two models were developed to describe (i) unbound and total LPV pharmacokinetics and (ii) LPV placental transfer. The pharmacokinetics was best described by a one-compartment model with first-order absorption and elimination. A pregnancy effect was found on maternal clearance (39% increase), whereas the treatment group (monotherapy versus triple therapy) or the genetic polymorphisms did not explain the pharmacokinetics or placental transfer of LPV. Efficient unbound LPV concentrations in nonpregnant women were similar to those measured during the third trimester of pregnancy. Our study showed a 39% increase of maternal total LPV clearance during pregnancy, whereas unbound LPV concentrations were similar to those simulated in nonpregnant women. The genetic polymorphisms selected did not influence the LPV pharmacokinetics or placental transfer. Thus, we suggest that the LPV dosage should not be increased during pregnancy.
引用
收藏
页码:5727 / 5735
页数:9
相关论文
共 39 条
[1]   Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal PregnancyA Database for Parameters Required in Physiologically Based Pharmacokinetic Modelling [J].
Khaled Abduljalil ;
Penny Furness ;
Trevor N. Johnson ;
Amin Rostami-Hodjegan ;
Hora Soltani .
Clinical Pharmacokinetics, 2012, 51 (6) :365-396
[2]   Lopinavir protein binding in HIV-1-infected pregnant women [J].
Aweeka, F. T. ;
Stek, A. ;
Best, B. M. ;
Hu, C. ;
Holland, D. ;
Hermes, A. ;
Burchett, S. K. ;
Read, J. ;
Mirochnick, M. ;
Capparelli, E. V. .
HIV MEDICINE, 2010, 11 (04) :232-238
[3]   Ways to fit a PK model with some data below the quantification limit [J].
Beal, SL .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (05) :481-504
[4]  
Beal SL, 1998, NONMEM USER GUIDES I
[5]   Changes in plasma protein binding have little clinical relevance [J].
Benet, LZ ;
Hoener, BA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :115-121
[6]   Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs [J].
Berno, Giulia ;
Zaccarelli, Mauro ;
Gori, Caterina ;
Tempestilli, Massimo ;
Antinori, Andrea ;
Perno, Carlo Federico ;
Pucillo, Leopoldo Paolo ;
D'Arrigo, Roberta .
BMC MEDICAL GENETICS, 2014, 15
[7]   Lopinavir Tablet Pharmacokinetics With an Increased Dose During Pregnancy [J].
Best, Brookie M. ;
Stek, Alice M. ;
Mirochnick, Mark ;
Hu, Chengcheng ;
Li, Hong ;
Burchett, Sandra K. ;
Rossi, Steven S. ;
Smith, Elizabeth ;
Read, Jennifer S. ;
Capparelli, Edmund V. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 54 (04) :381-388
[8]   Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues [J].
Blanche, S ;
Tardieu, M ;
Rustin, P ;
Slama, A ;
Barret, B ;
Firtion, G ;
Ciraru-Vigneron, N ;
Lacroix, C ;
Rouzioux, C ;
Mandelbrot, L ;
Desguerre, I ;
Rötig, A ;
Mayaux, MJ ;
Delfraissy, JF .
LANCET, 1999, 354 (9184) :1084-1089
[9]   Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment [J].
Bouillon-Pichault, Marion ;
Jullien, Vincent ;
Azria, Elie ;
Pannier, Emmanuelle ;
Firtion, Ghislaine ;
Krivine, Anne ;
Compagnucci, Alexandra ;
Taulera, Olivier ;
Finkielsztejn, Laurent ;
Chhun, Stephanie ;
Pons, Gerard ;
Launay, Odile ;
Treluyer, Jean-Marc .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (06) :1223-1232
[10]   Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study) [J].
Breilh, D ;
Pellegrin, I ;
Rouzés, A ;
Berthoin, K ;
Xuereb, F ;
Budzinski, H ;
Munck, M ;
Fleury, HJA ;
Saux, MC ;
Pellegrin, JL .
AIDS, 2004, 18 (09) :1305-1310